Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Rev. peru. biol. (Impr.) ; 28(1): e19743, Jan-Mar 2021. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1289879

ABSTRACT

Abstract Acidithiobacillus ferrivorans is a psychrotolerant acidophile capable of growing and oxidizing ferrous and sulphide substrates at low temperatures. To date, six genomes of this organism have been characterized; however, evidence of a plasmid in this species has been reported only once, whereby there is no conclusive role of the plasmids in the species. Herein, two novel plasmids of A. ferrivorans PQ33 were molecularly characterized and compared at a genomic scale. The genomes of two plasmids (12 kbp and 10 kbp) from A. ferrivorans PQ33 (NZ_LVZL01000000) were sequenced and annotated. The plasmids, named pAfPQ33-1 (NZ_CP021414.1) and pAfPQ33-2 (NZ_CP021415.1), presented 9 CDS and 13 CDS, respectively. In silico analysis showed proteins involved in conjugation (TraD, MobA, Eep and XerD), toxin-antitoxin systems (HicA and HicB), replication (RepA and DNA binding protein), transcription regulation (CopG), chaperone DnaJ, and a virulence gene (vapD). Furthermore, the plasmids contain sequences similar to phosphate-selective porins O and P and a diguanylate cyclase-phosphodiesterase protein. The presence of these genes suggests the possibility of horizontal transfer, a regulatory system of plasmid maintenance, and adhesion to substrates for A. ferrivorans species and PQ33. This is the first report of plasmids in this strain.


Resumen Acidithiobacillus ferrivorans es un acidófilo psicrotolerante capaz de hacer crecer y oxidar sustratos ferrosos y sulfurosos a bajas temperaturas. Hasta la fecha se han caracterizado seis genomas de este organismo; sin embargo, la evidencia de un plásmido en esta especie ha sido informado solo una vez, por lo que no hay un rol concluyente de los plásmidos en la especie. Aquí, dos plásmidos novedosos de A. ferrivorans PQ33 se caracterizaron molecularmente y se compararon a escala genómica. Se secuenciaron y anotaron los genomas de dos plásmidos (12 kpb y 10 kpb) de A. ferrivorans PQ33 (NZ_LVZL01000000). Los plásmidos, denominados pAfPQ33-1 (NZ_CP021414.1) y pAfPQ33-2 (NZ_CP021415.1), presentaron 9 CDS y 13 CDS, respectivamente. El análisis in silico mostró proteínas involucradas en la conjugación (TraD, MobA, Eep y XerD), sistemas de toxina-antitoxina (HicA y HicB), replicación (RepA y proteína de unión al ADN), regulación de la transcripción (CopG), chaperona DnaJ y un gen de virulencia (vapD). Además, los plásmidos contienen secuencias similares a las porinas selectivas de fosfato O y P y una proteína diguanilato ciclasa-fosfodiesterasa. La presencia de estos genes sugiere la posibilidad de transferencia horizontal, un sistema regulador de mantenimiento de plásmidos y adhesión a sustratos para especies de A. ferrivorans y PQ33. Este es el primer informe de plásmidos en esta cepa.

2.
Mem. Inst. Oswaldo Cruz ; 115: e200184, 2020. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-1135263

ABSTRACT

BACKGROUND Carrion's disease (CD) is a neglected biphasic illness caused by Bartonella bacilliformis, a Gram-negative bacteria found in the Andean valleys. The spread of resistant strains underlines the need for novel antimicrobials against B. bacilliformis and related bacterial pathogens. OBJECTIVE The main aim of this study was to integrate genomic-scale data to shortlist a set of proteins that could serve as attractive targets for new antimicrobial discovery to combat B. bacilliformis. METHODS We performed a multidimensional genomic scale analysis of potential and relevant targets which includes structural druggability, metabolic analysis and essentiality criteria to select proteins with attractive features for drug discovery. FINDINGS We shortlisted seventeen relevant proteins to develop new drugs against the causative agent of Carrion's disease. Particularly, the protein products of fabI, folA, aroA, trmFO, uppP and murE genes, meet an important number of desirable features that make them attractive targets for new drug development. This data compendium is freely available as a web server (http://target.sbg.qb.fcen.uba.ar/). MAIN CONCLUSION This work represents an effort to reduce the costs in the first phases of B. bacilliformis drug discovery.


Subject(s)
Humans , Bartonella Infections/drug therapy , Bartonella bacilliformis/drug effects , Anti-Bacterial Agents/therapeutic use , DNA, Bacterial/isolation & purification , DNA, Bacterial/genetics , Polymerase Chain Reaction , Genomics , Bartonella bacilliformis/isolation & purification , Bartonella bacilliformis/genetics
4.
Rev. peru. med. exp. salud publica ; 35(4): 363-641, oct.-dic 2018. ilus, tab
Article in Spanish | LILACS | ID: biblio-1020775

ABSTRACT

Con el objetivo de caracterizar y determinar la frecuencia de genes que codifican metalo-β-lactamasas (MBL) en aislados clínicos de Pseudomonas aeruginosa (P. aeruginosa), se realizó un estudio transversal en el Hospital Militar Central (HMC) de Lima, Perú, entre enero y setiembre del 2016. Se analizaron 76 aislados de P. aeruginosa con sensibilidad disminuida a carbapenémicos y resistentes a ceftazidima. La detección fenotípica de MBL se realizó por el método de sinergia de doble disco entre imipenem y meropenem frente al ácido etilendiaminotetraacético (EDTA), y la identificación de los genes por reacción en cadena de la polimerasa. De los 76 aislados, 24 (31,6 %) fueron positivos para MBL por el método fenotípico, confirmándose genéticamente todos. Se encontró el gen blaIMP en 23/24 (95,8 %) y blaVIM en 1/24 (4,2 %). Ningún aislado presentó blaNDM. El gen blaIMP resultó ser el más frecuente entre los aislados clínicos de P. aeruginosa no sensibles a carbapenémicos en el HMC.


hat codify metallo-β-lactamases (MBL) in clinical isolates of Pseudomona aeruginosa (P. aeruginosa), a cross-sectional study was conducted in the Central Military Hospital (HMC) of Lima, Peru, between January and September, 2016. Seventy-six (76) isolates of P. aeruginosa with diminished sensitivity to carbapenemes and resistant to ceftazidime were analyzed. The phenotype detection of MBL was made by double disc synergy between imipenem and meropenem versus ethylenediaminetetraacetic acid (EDTA), and the identification of the genes was performed by polymerase chain reaction. Of the 76 isolates, 24 (31.6%) were positive for MBL by the phenotype method, genetically confirming all. The blaIMP gene was found in 23/24 (95.8%) and blaVIM in 1/24 (4.2%). No isolate had blaNDM. The blaIMP gene turned out to be the most frequent among clinical isolates of P. aeruginosa not sensitive to carbapenemics at this Hospital.


Subject(s)
Humans , Pseudomonas aeruginosa/genetics , Bacterial Proteins/genetics , beta-Lactamases/genetics , Peru , Pseudomonas aeruginosa/isolation & purification , Pseudomonas aeruginosa/enzymology , Bacterial Proteins/analysis , beta-Lactamases/analysis , Cross-Sectional Studies , Hospitalization , Hospitals, Military
SELECTION OF CITATIONS
SEARCH DETAIL